MONTREAL--(EON: Enhanced Online News)--Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced that an updated interim analysis from its latest REP 401 clinical trial has been selected by the Asia Pacific Association for the Study of Liver (APASL) for oral presentation at its annual meeting to be held February 15-19, 2017 in Shanghai, China.
The REP 401 protocol (NCT02565719) is a randomized, controlled trial assessing the safety and efficacy of its first in class HBsAg release inhibitor, REP 2139 and a REP 2139 derivative with improved plasma and tissue clearance (REP 2165) in combination with tenofovir disoproxil fumarate (TDF) and pegylated interferon alpha-2a (peg-IFN) in treatment naïve patients with chronic HBeAg negative HBV infection.
The updated clinical analysis, to be presented on Feb 18th (OP 116) will include substantially longer exposure analysis in experimental and control groups and include for the first initial analysis of antiviral response when NAP therapy is added 24 weeks after peg-IFN therapy in crossover patients in the adaptive comparator control arm.
Replicor’s presentation from APASL 2017 will be available on the company’s website following its disclosure at the meeting at www.replicor.com/science/conference-presentations. For further information about the 2017 APASL Meeting visit: http://www.apasl2017.org/#/.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.